Odonate Therapeutics (NASDAQ:ODT) Lowered to “Hold” at Zacks Investment Research

Zacks Investment Research lowered shares of Odonate Therapeutics (NASDAQ:ODT) from a buy rating to a hold rating in a report released on Tuesday morning, Zacks.com reports.

According to Zacks, “Odonate Therapeutics, LLC is a pharmaceutical company. It engaged in the development of therapeutics to improve and extend the lives of patients with cancer. The company focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic breast cancer. Odonate Therapeutics, LLC is based in SAN DIEGO, United States. “

Separately, ValuEngine cut Odonate Therapeutics from a hold rating to a sell rating in a report on Wednesday, October 2nd.

Shares of NASDAQ ODT traded up $0.97 during trading on Tuesday, hitting $33.10. The company had a trading volume of 98,400 shares, compared to its average volume of 112,896. The firm has a market capitalization of $1.03 billion, a P/E ratio of -9.09 and a beta of 1.83. The stock has a 50 day simple moving average of $29.21 and a 200 day simple moving average of $29.63. Odonate Therapeutics has a 12 month low of $11.54 and a 12 month high of $43.75.

Institutional investors have recently made changes to their positions in the company. TD Asset Management Inc. boosted its holdings in shares of Odonate Therapeutics by 57.2% in the 2nd quarter. TD Asset Management Inc. now owns 28,393 shares of the company’s stock worth $1,042,000 after purchasing an additional 10,331 shares during the period. Eagle Asset Management Inc. boosted its holdings in Odonate Therapeutics by 5.3% during the 3rd quarter. Eagle Asset Management Inc. now owns 528,124 shares of the company’s stock valued at $13,747,000 after acquiring an additional 26,811 shares during the period. BlackRock Inc. boosted its holdings in Odonate Therapeutics by 55.4% during the 2nd quarter. BlackRock Inc. now owns 578,823 shares of the company’s stock valued at $21,236,000 after acquiring an additional 206,238 shares during the period. Janus Henderson Group PLC boosted its holdings in Odonate Therapeutics by 2.6% during the 2nd quarter. Janus Henderson Group PLC now owns 1,315,426 shares of the company’s stock valued at $48,262,000 after acquiring an additional 33,325 shares during the period. Finally, Samsara BioCapital LLC boosted its holdings in Odonate Therapeutics by 3.4% during the 2nd quarter. Samsara BioCapital LLC now owns 615,850 shares of the company’s stock valued at $22,596,000 after acquiring an additional 20,000 shares during the period. Hedge funds and other institutional investors own 96.64% of the company’s stock.

About Odonate Therapeutics

Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.

Read More: What is a good rate of return for a mutual fund?

Get a free copy of the Zacks research report on Odonate Therapeutics (ODT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.